RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Clinical trial NCT05733611 · TERMINATED

Trial details

NCT number: NCT05733611
Sponsor: Replimune, Inc.
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Refractory Metastatic Colorectal Cancer pMMR MSS

Start date: 2023-06-29
Primary completion: 2025-08-18
Enrollment: 5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.